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Abstract
Purpose:  To  compare  contrast  sensitivity  (CS)  in multi-transfused  -thalassemia  patients  who
received  deferoxamine  with  those  who  received  Osveral.
Methods:  In  this  cross  sectional  study  a  total  of  60  -thalassemia  patients  (30  used  deferoxam-
ine and  30  used  deferasirox)  were  regarded  as  case  group  and  30  age  and  sex matched  healthy
subjects were  selected  as  control  group.  All  subjects  had  a  set  of  examinations  including  refrac-
tion, visual  acuity,  Biomicroscopy,  ophthalmoscopy  and  CS.  Contrast  threshold  was  assessed  with
the use  of  Freiberg  visual  acuity  and  contrast  test  under  the  mesopic  light  condition  for  three
frequencies;  1, 5,  15  cpd.  All  data  analysis  was  performed  using  SPSS,  version  17.
Results: In  visual  acuity  tests,  thalassemic  patients  did  not  have  any  problem.  Contrast  thresh-
old was  higher  in thalassemic  patients  who  infuse  deferoxamine  (1.87  ±  0.63,  1.46  ± 0.81,
and 2.96  ±  1.68  in 1,  5, and 15  cpd,  respectively)  than  that  of  those  who  intake  deferasirox
(1.74 ± 0.80  (P  =  0.743),  0.99  ±  0.74  (P  = 0.047),  and  2.42  ± 1.36  (P =  0.321)  for  1, 5,  and  15  cpd,
respectively),  and  also  than  healthy  patients  (1.33  ±  0.58  (P = 0.009),  0.95  ±  0.68  (P = 0.022),
and 2.24  ±  1.23  (P  =  0.135)  for  1,  5,  and  15  cpd,  respectively).  Comparing  those  who  used
deferasirox with  healthy  subjects,  contrast  threshold  was  higher  in deferasirox  group  at  all
special  frequencies  (P  > 0.05).  No  significant  relationship  was  observed  between  CS  values  and
duration  of  transfusion,  serum  ferritin  concentration  and dose  of  chelation  therapy  (P  >  0.05).
Conclusions:  CS  tests  can detect  visual  disturbance  in thalassemic  patients  before  the  impair-
ment of  visual  acuity.  It is  suggested  that  CS  tests  be  included  in  their  regular  eye  examination.
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Comparación  de la sensibilidad  de contraste  en  los  pacientes  con  -Talasemia
tratados  con  Deferoxamina  o Deferasirox
Resumen
Objetivo:  Comparar  la  sensibilidad  de contraste  (SC)  en  pacientes  multitrasfundidos  con  -
talasemia  y  tratados  con  deferoxamina  u  Osveral.
Métodos:  En  este  estudio  transversal,  un  total de 60  pacientes  con  -talasemia  (30  tratados  con
deferoxamina  y  30  con  deferasirox)  fueron  considerados  como  grupo  de estudio,  y  30  sujetos
sanos pareados  por  edad  y  sexo  fueron  seleccionados  como  grupo  control.  A todos  los  sujetos  se
les realizó  una  serie  de  exámenes  que  incluyeron  refracción,  agudeza  visual,  biomicroscopía,
oftalmoscopía  y  SC. El umbral  de contraste  se  valoró  mediante  la  prueba  de  agudeza  visual  y
contraste  de  Freiberg,  en  condiciones  de  visión mesópica  para  tres  frecuencias:  1,  5  y  15  cpd.
Todos los  análisis  de los  datos  se  realizaron  utilizando  SPSS,  versión  17.
Resultados:  En  las pruebas  de agudeza  visual  los  pacientes  con  talasemia  no tuvieron  ningún
problema.  El umbral  de  contraste  fue superior  en  los  pacientes  con  talasemia  a  quienes  se
infundió deferoxamina  (1,87±0,63,  1,46±0,81  y  2,96±1,68  en  1,  5 y  15  cpd,  respectivamente)
que en  los pacientes  tratados  con  deferasirox  (1,74±0,8  (P=0,743),  0,99±0,74  (P=0,047)  y
2,42±1,36 (P=0,321)  para  1, 5 y  15  cpd,  respectivamente),  y  también  en  los  pacientes  sanos
(1,33±0,58 (P=0,009),  0,95±0,68  (P=0,022)  y  2,24±1,23  (P=0,135)  para  1, 5  y  15  cpd,  respecti-
vamente).  Al  comparar  los  pacientes  tratados  con  deferasirox  y  los sujetos  sanos,  el  umbral  de
contraste  fue  superior  en  el grupo  de  deferasirox  para  todas  las  frecuencias  especiales  (P>0,05).
No se  observó  una  relación  significativa  entre  los  valores  de  SC  y  la  duración  de  la  trasfusión,
la concentración  de  ferritina  sérica  y  la  dosis  de  la  terapia  de quelación  (P>0,05).
Conclusiones:  Las  pruebas  de SC  pueden  detectar  la  alteración  visual  en  los  pacientes  con
talasemia  con  anterioridad  al  deterioro  de  la  agudeza  visual.  Sugerimos  la  inclusión  de  las
pruebas  de  SC  en  su  examen  ocular  regular.
©  2018  Spanish  General  Council  of  Optometry.  Publicado  por  Elsevier  Espan˜a, S.L.U.  Este  es  un
art´ıculo Open  Access  bajo  la  licencia  CC  BY-NC-ND  (http://creativecommons.org/licenses/by-
nc-nd/4.0/).
Introduction
Thalassemia  which  is  one  of  the  most  common  sever  genetic
blood  disorders  can  lead  to  different  ocular  involvements.1,2
Ocular  findings  in these patients  may  correlate  to disease
itself,  iron  overload  due  to  regular  blood  transfusion  or
chelating  agents  used to  reduce  iron  store  in their  body.3
Since  1970,  iron  chelation  therapy  has been  used to
reduce  iron  overload  in  thalassemic  patients.4 Deferoxamine
(DFO,  Desferal
®
) is  the  oldest  iron  chelator  which  should  be
injected  subcutaneously  usually  in  the duration  of 8--12  h.
Injection  of  DFO  is  its  main  problem.  So  in recent  years
some  oral  chelators  such as  deferiprone  and  deferasirox
were  introduced.5,6
Ocular  complications  of thalassemia  and  its  therapeu-
tic  modalities  has  been  reported  by  many  sources.1,3,7,8 But
there  are  only  few studies  that  evaluate  contrast  sensitiv-
ity  in  these  patients.9--11 Impaired  contrast  sensitivity  in  the
presence  of  normal  visual  acuity  can  detect  early  changes
in  the  visual  system  of  these  patients.  To our  knowledge,  no
study  has  been  done  to  compare  contrast  sensitivity  in  tha-
lassemia  major  patients  who  used  different  chelator  agents.
Gartaganis  et al. in 2000  investigated  contrast  sensitivity
function  in  -thalassemia  major  patients  treated  by  reg-
ular  blood  transfusion  and  subcutaneous  infusion  of DFO.
They  used  the  Vector Vision  CSV-1000  contrast sensitivity
test  and  conclude  that  contrast  sensitivity  function  in all
-thalassemia  patients  was  significantly  lower  than normal
subjects.10 Spyridon  et al.  in 2010  used  B-VAT  II SG mentor
visual  acuity  tester  to  measure  contrast  sensitivity  in -
thalassemia  major patients  and  found  significant  difference
between  contrast  sensitivity  of  thalassemic  and normal  sub-
jects  in  special  frequencies  of  2, 3, and 6 cycles  per  degree
(cpd).11
According  to  high  prevalence  of  -thalassemia  in Iranian
population,  particularly  in north  of  Iran12 and  its  ocular  side
effects  which influence  their  quality  of  life, evaluation  of
contrast  sensitivity  of  these  patients  using  cheap,  simple
and  reliable  test  to  identify  early  changes  in  their  ocular
system  is  fundamental.
The  primary  objective  of  this  study  was  to compare  con-
trast  sensitivity  in multi-transfused  -thalassemia  patients
who  received  subcutaneous  DFO with  those  who  received
Osveral  (an  Iranian  made  deferasirox)  and  normal  subjects.
We  also  investigated  the correlation  of  contrast  sensitivity
with  serum  ferritin  level,  duration  of blood  transfusion  and
dosage  of  chelation  therapy.
Methods
This  cross  sectional  study  was  carried  out in the  thalassemic
research  center  of  Mazandaran  province,  Iran.  Thalassemic
patients  in  Mazandaran  are  all  registered  in this center
in  order  to  receive  treatment.  Study  participants  were
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selected  with  simple  random  sampling  method  from  the list
of  thalassemic  patients  with  the use  of  computerized  table.
Informed  written  consent  was  obtained  from  all partici-
pants  after  a detailed  explanation  of  the  nature  of the study
according  to  the  code  of  ethics  in the  declaration  of  Helsinki
protocol.  Selected  participants  were  visited  by  hematolo-
gist  and  those with  no  diabetes  or  other  systemic  disease
who  received  chelator  agents  (DFO  or  deferasirox)  for  at
least  2 years  were  referred  for ophthalmic  and optometric
evaluation.
An ophthalmologist  examined  anterior  and posterior  seg-
ments  of  the eye  with  the use  of  slit  lamp  (Model  BQ  900:
Haag  Streit,  Bern,  Switzerland)  and  ophthalmoscope  (Oph-
thalmoscope,  Heine  Beta  200,  Germany)  and those  with  any
ophthalmic  pathology,  aphakia,  strabismus,  corneal  and lens
opacities,  history  of ocular  surgery,  history  of  ocular  trauma
and  pathologic  myopia  were  excluded.
Then  an  optometrist  began  optometric  examinations.
Uncorrected  visual  acuity  (UCVA)  was  measured  monocu-
larly  using  the  Snellen  chart  at 6  m.  Refraction  was  measured
using  the  autorefractometer  (Topcon  RM8800)  and  checked
with  a  Heine  streak  retinoscope  (HEINE  Optotechnik).  Those
with  UCVA  worse  than  20/20  had  subjective  refraction  and
then  best  corrected  visual  acuity  (BCVA) was  recorded.
Those  with  BCVA  worse  than  20/20  and those  with  spherical
refractive  error  of  more  than  1.5  diopter  (D)  and  astigmatism
greater  than  1 D were  excluded  from  the  study.
Finally,  60  patients  with  -thalassemia  (30  used DFO
and  30  used  deferasirox)  ranging  in age  between  20  to  30
years  and  30  age and  sex  matched  healthy  subjects  were
enrolled  for the study.  Healthy  subjects  were  selected  ran-
domly  amongst  the  staff  of the thalassemia  research  center.
Contrast  sensitivity  test  was  done  for all  selected  subjects.
Contrast  threshold  was  measured  for  each  eye  with  the
Freiberg  visual  acuity  and  contrast  test  (FrACT  version  3.7.1)
under  mesopic  light  condition  for  three  frequencies;  1,  5,
15  cpd.
FrACT  is  a computer  program  that uses eight  alter-
native  force  choices  and  the best  parameter  estimation
by  sequential  testing  (PEST)  algorithm  for  threshold
determination.13,14 It  enables  automatic  and  observe  inde-
pendent  determination  of contrast  threshold  at different
special  frequencies  using  sinusoidal  gratings  or  special  opto-
type  size.  In this study,  gratings  were presented  in 8
different  orientations.  The  patient  tell  the  perceived  direc-
tion  of  gratings  and  the  investigator  entered  the response.
Twenty-four  trials  comprised  one  run and  two  runs  were
taken  for  each  condition.  At  the  end  of  the test,  contrast
threshold  was  computed  in percent  and  showed  on  the
screen.
Contrast  threshold  was  tested  monocularly  at a distance
of  4  m.  In  those  with  UCVA  worse  than 20/20,  contrast  sen-
sitivity  evaluation  was  performed  using  carefully  cleansed
trial  lenses  (Oculus,  Wetzler,  Germany).
Descriptive  and  inferential  data  analysis were carried
out  using  SPSS.17  software  (SPSS  for Windows,  SPSS  Inc.,
Chicago,  IL,  USA).  Kolmogorov--Smirnov  test  for normality
indicated  that  the  distribution  of  spherical  and  cylin-
drical  refractive  errors  was  not  normal  and therefore
non-parametric  tests  were  used  for statistical  analysis  of
these  parameters.  Median  test,  independent  sample  T Test,
One-way  ANOVA  and  Pearson  correlation  were used where
Table  1 Spherical  and  cylindrical  refractive  errors  in two
thalassemic  and  control  groups.1
Sphere  Cylinder
Median(IQR2=Q1-Q3)  Median(IQR  = Q1-Q3)
Desferal  group 0.00(0.00-0.25)  -0.25(-0.50-0.00)
Osveral  group  0.00(0.00-0.50)  0.00(-0.31-0.00)
Control  group  0.00(0.00-0.00)  -0.25(-0.50-0.00)
P-value  0.005  0.478
1 Median test  used for analysis.
2 IQR = (Q1-Q3) = Interquartile range.
applicable.  A  statistical  significant  difference  was  consid-
ered  for  P < 0.05.
Results
In this  study,  60  thalassemic  patients  were  studied  includ-
ing thirty  patients  from  desferal  group  and 30 from  Osveral
group.  As  contrast  thresholds  in  the right  and  left  eye
were  correlated  (Pearson  correlation;  r =  0.847,  P  = 0.000),
the data  from  the right  eye  were  considered.  The  mean
age  of thalassemic  patients  in Desferal  and Osveral  groups
were  24.33  ±  3.44  and  23.70  ±  3.39,  respectively.  The  con-
trol  group  included  30  healthy  subjects  with  the mean  age
of  24.70  ± 3.46.  The  age  of  included  subjects  in case  and
control  groups  ranged  from  20  to 30  years  old.  There  was
no  significant  difference  for  sex  and age  between  groups
(P  = 0.731,  P =  0.524,  respectively).
Table  1  shows  median  and  interquartile  range  (IQR)  of
spherical  and cylindrical  refractive  errors  in the  two  tha-
lassemic  and  control  groups.  Median  test  was  used  for
testing  whether  study  groups  differ  in their  median  value
or  not.  According  to  the table,  significant  difference  was
found  between  spherical  refractive  errors  of  three  groups
(P  = 0.005),  but  no  significant  difference  was  found  in cylin-
drical  refractive  errors  (P = 0.478).
All  thalassemic  patients  were  asymptomatic  and  oph-
thalmic  examinations  did not  revealed  any pathological  and
structural  problem  in their  ocular  system.  The  mean  ±  SD
values  for  best  corrected  visual  acuity  was  1  min  of  arc  in all
participants.
Table  2  shows  the  characteristics  of  thalassemic  patients
based  on  the type of  chelator  they  received.
The  mean  ±  SD  contrast  threshold  of  all participants  are
given  in Table  3.  Contrast  threshold  was  evaluated  for  three
spatial  frequencies  (1,  5,  and  15 cpd).  One-way  ANOVA  test
showed  a significant  difference  between  contrast  threshold
of  patients  in  Desferal  and control  groups  in  all  evaluated
special  frequencies.  Also,  contrast  threshold  of Desferal
group  for  all  special  frequencies  was  higher  than  that  of
Osveral  group,  although  the  difference  was  not statistically
significant  for  1  and 15  cpd.  In  the comparison  of contrast
threshold  in  those  who  used deferasirox  with  healthy  sub-
jects,  contrast  threshold  was  higher  in deferasirox  group  at
all  special  frequencies,  but  the  difference  was  not  signifi-
cant.
Table  4 represents  the Pearson  correlation  of contrast
threshold  with  serum  ferritin  level,  dose of  chelation  ther-
apy and  duration  of  blood  transfusion.  According  to  the
Contrast  sensitivity  in  -thalassemia  patients  171
Table  2  Comparison  of characteristics  of  thalassemic  patients  based  on the  type  of  chelator  they  received1
Duration  of  blood  transfusion  (Year)  Serum  ferritin  level  (mg/L)  Chelator  dosage  (mg/kg/day)
Desferal  Group  22.4  ± 4.14  (14-29)  2575  ± 1678(400-7000)  36.82  ± 9.56  (16-65)
Osveral Group  18.53  ±  3.86  (10-28)  1951  ± 1336  (575-7000)  24.13  ± 5.59  (8-35)
P-Value 0.000  0.11  0.000
1 Independent sample T Test used for analysis
Table  3  Mean  contrast  threshold  of  both  thalassemic  and  healthy  subjects.1
Special  Frequencies  Study  Group  Contrast  threshold  mean  ±  SD  [Range2]  P-value
Desferal  &
Osveral
Desferal  &
Normal
Osveral  &
Normal
1  cpd  Desferal  1.87  ±  0.63  [0.51-3.44]  0.743  0.009  0.061
Osveral 1.74  ±  0.8  [0.51-3.91]
Normal  1.33  ±  0.58  [0.51-2.79]
5 cpd  Desferal  1.46  ±  0.81  [0.50-2.95]  0.047  0.022  0.949
Osveral 0.99  ±  0.74  [0.50-2.97]
Normal  0.95  ±  0.68  [0.51-2.54
15 cpd  Desferal  2.96  ±  1.68  [0.51-6.88]  0.321  0.135  0.879
Osveral 2.46  ±  1.36  [0.76-6.54]
Normal  2.24  ±  1.23  [0.51-5.98]
1 Determined by one-way ANOVA and Tukey post hoc test.
2 Range = [Min-Max].
Table  4  The  Correlation  of  contrast  threshold  with  serum  ferritin  level,  dose  of  chelation  therapy  and  duration  of  blood
transfusion.1
Serum  ferritin  level Duration  of  blood  transfusion  Chelator  dose
P r  p  r p  r
Contrast  threshold  Desferal  1 cpd 0.98  .004  0.03  -0.39  0.47  0.136
5 cpd 0.06  0.346  0.18  0.246  0.19  0.246
15 cpd  0.22  0.230  0.90  0.023  0.42  0.150
Osveral  1 cpd 0.54  0.115  0.35  0.174  0.24  0.219
5 cpd 0.31  0.191  0.70  0.071  0.29  0.199
15 cpd  0.17  0.257  0.27  0.204  0.17  0.254
1 Pearson Correlation.
table,  no significant  correlation  was  found  between  contrast
threshold  and these  parameters.
Discussion
Contrast  sensitivity  has  been considered  as  an  important
indicator  of  visual  function  by  some researchers  and it  is
claimed  that  its  evaluation  can  better  discriminate  oph-
thalmic  disorders  compared  to  Snellen  visual  acuity.15,16 As
the  results  of  this study  showed,  contrast  threshold  was
higher  in  patients  with  major  thalassemia  who  infuse  DFO
than  that  of those  who  intake  deferasirox  and  also  healthy
patients  at  all  spatial  frequencies.  In the comparison  of con-
trast  threshold  in those  who  used deferasirox  with  healthy
subjects,  contrast  threshold  was  higher  in  deferasirox  group
at  all  special  frequencies,  but  the  difference  was  not sig-
nificant.  While  in  conventional  visual  acuity  tests  measured
with  the Snellen  chart,  thalassemic  patients  did  not  have
any  problem.  No  statistically  significant  relationship  was
observed  between  contrast  sensitivity  values  and duration
of  transfusion,  mean  serum  ferritin  concentration  and  dose
of  chelation  therapy.
Previous  studies  have also  confirmed  similar  findings;
Gartaganis  et al. have found  that  contrast  sensitivity  func-
tion  in  all  beta-thalassemic  patients  with  normal  Snellen
visual  acuity  was  significantly  lower  compared  to  the  normal
control  subjects  for  all  spatial  frequencies  tested.10 Spyri-
don  et  al.  also  reported  reduced  contrast  sensitivity  values  in
patients  with  major  thalassemia  than  the values  for  normal
subjects  for  frequencies  of  2, 3 and  6 cpd.11
Ocular  complications,  such  as  lens  opacity,  macular
degeneration,  retinal  vascular  changes  and  RPE  degenera-
tion  have been  reported  in patients  with  major  thalassemia
in previous  studies.1,3,7,8,17 The  mechanism  is  not  exactly
clear,  some  researchers  believe  that  ocular  abnormalities
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were  mainly  because  of  iron  overload  and  not  secondary
to  chelation  therapy  while  others  claim  that  chelator
administration,  especially  DFO,  has toxic  effects  and can
affect  the  eye  in  many  ways.3 Also,  unstable  blood
hemoglobin  values  in spite  of periodic  blood  transfusion  can
cause  chronic  retinal  hypoxia  and  damage  function  of  the
retinal  cells.10
In the  current  study,  we  did  not  include  those  with
any  pathologic  eye  problems  or  systemic  diseases,  such  as
diabetes  which  can adversely  affect  visual  system.  It is
claimed  that  in diabetic  patients  due  to  disruption  of  the
blood  retinal  barrier, DFO  is able  to  cross  to retina  more
than  in  normal  patients  and  consequently  can  cause  more
toxic  problems.18,19 On the other  hand,  we  exclude  tha-
lassemic  patients  with  high  refractive  errors,  especially  high
myopia.  It  seems that in  these  patients  due  to  changes  in
Bruch  layer,  iron  deposition  would be  higher  and  subse-
quently  more  side  effect  is  expected.20 It should  be noted
that,  similar  to  previous  studies,  despite  the  lack  of obvi-
ous  pathological  and  structural  changes  in the ocular system
of  our  selected  thalassemic  patients,  their  contrast  sen-
sitivity  was  considerably  lower  than  in healthy  subjects,
especially  in  those  who  infuse  DFO.  However,  although  we
do  not  find  any  obvious ocular  pathology  in  our  selected
patients,  previous  studies  indicated  that  they  may  reveal
some  abnormalities  with  the  use  of  electro-diagnostic  tests,
fluorescein  angiography  or  tests  such  as  perimetery.1,3,21 For
instance,  Gartaganis  et al. did  not  found  any  problem  in
slit  lamp  examination  of  their  patients  but  angiod  streak
and  RPE  degeneration  were  revealed  in 13%  of  their  sub-
jects  with  the  use  of  fluorescein  angiography.  They  also
reported  that  contrast  sensitivity  loss  in those  who  revealed
ocular  pathology  with  the  use  of  fluorescein  angiography
was  higher  than  that  of  those  who  do not  showed  any
problem.10
The  result  of our study  showed  a  significant  difference
between  contrast  sensitivity  of  thalassemic  patients  who
used  different  chelator  drugs. To  our  knowledge,  this  is
the  first  study  that  compare  contrast  sensitivity  in tha-
lassemic  patients  using  different  chelator  agents.  In a
previous  study,  we  evaluate  ocular  abnormalities  in tha-
lassemic  patients  who  used different  chelator  drugs.  In
that  study,  in order  to evaluate  the effect  of different
type  of  chelators,  thalassemia  patients  were  divided  into
three  groups  based on  the type  of  chelators  they  received:
Group  A  received  blood  transfusion  and  subcutaneous  DFO,
Group  B  blood  transfusion  combined  with  subcutaneous
DFO  and  oral  deferiprone,  and  Group  C  blood  transfusion
along  with  Osveral.  Although  no  significant  difference  was
found  between  the prevalence  of  different  type  of  ocu-
lar  abnormalities  among  three  thalassemic  groups  in  that
study,  among  evaluated  ocular  abnormalities,  RPE  degen-
eration  was  slightly  higher  in those  who  used desferal  in
comparison  to  those  who  used Osveral.1 In our  present
study,  contrast  sensitivity  in  desferal group  was  consid-
erably  lower  than  that  of  Osveral  group.  More  reduction
of  contrast  sensitivity  in those  who  used desferal  confirm
that  they  may  reveal  some  abnormalities  in  more  detailed
examinations.
There  are  several  studies  that  investigate  the relation-
ship  between  the  dose  of chelator  agents,  mean  serum
ferritin  level  and  the number  of  blood  transfusions  with
ocular  problems.1,8,10,22 In  this  study,  we  did not observe  any
relationship  between  duration  of blood  transfusion,  chela-
tor  dose  and  serum  ferritin  level with  contrast  sensitivity,
which  was  similar  to  Gartaganis  findings.  They  conclude  that
the  main  reason  for  contrast  sensitivity  loss  could  be chronic
retinal  hypoxia  and  other  factors  such as  duration  of  transfu-
sions,  the duration  of  chelator  therapy and  the serum  ferritin
concentrations  are of lesser importance.10 In  our  previous
study  on  another group  of  thalassemic  patients,  we  found
a  significant  positive  correlation  between  the prevalence
of  ocular  abnormalities  and  number  of  blood  transfusions
but  not  with  mean  serum  ferritin  level  and  dose of  chela-
tor  agents.1 However,  considering  different  age  range  of  the
participants  in different  studies,  it is  difficult  to  make  an
accurate  comparison.
However,  despite  widespread  claims  of  the  effective-
ness  of DFO  dosage  on  visual  function,22 we  do not  find
any  correlation  between  doses  of  chelator  agents  and  con-
trast  sensitivity  reduction.  This  could  be due  to  low dose
of  chelator  that  our  patients  received.  Cohen  et  al. indi-
cated  that  DFO doses  lower  than  50  mg/kg/day  cannot  cause
structural  eye  problems  and  only may  lead  to hearing  loss.23
Ninety  eight  percent  of  our  subjects  received  lower  than
50  mg/kg/day  of  chelators.
Our study  has  some  limitations;  in  this study  those  who
were  taking  Osveral  were on  DFO  previously,  so loss  of con-
trast  sensitivity  can  be related  to  their  previous  treatment.
Also,  due  to  the limited  number  of  cases  and  the short
time  that  they  intake  Osveral,  we  could  not  fully  evaluate
effect  of  Osveral  on  contrast  sensitivity  function  of  these
patients.  Also,  we do not  evaluate  and  exclude  patients  with
dry  eye.  As  there  is  evidence  about the degree  of  associa-
tion  between  thalassemia  and dry  eye,1 which could  have
some  effects  on  contrast  sensitivity  results,  it was  better to
exclude  those  with  dry  eye.
As  we  know, in many  ophthalmic  disorders  contrast sen-
sitivity  tests  can  detect  visual  disturbances  before  the
impairment  of  visual  acuity.  According  to this issue,  it is sug-
gested  that  contrast  sensitivity  tests  be included  in regular
eye  examination  of  thalassemic  patients  and in the  event of
diagnosis  any  reduction  in contrast  sensitivity,  it  is  better
to  refer  patients  to  hematologist  to  evaluate  the possibil-
ity  of  changing  their  treatment  regimen  and prevent  further
complications.
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